|
| PamGene receives the 'Andersen Most Promising Biotech Company Award 2001' | | | "s-HERTOGENBOSCH, THE NETHERLANDS - 28th November, 2001
During this week’s conference "Venture Capital Biotechnology 2001" in Rotterdam, The Netherlands, PamGene received "The Andersen Most Promising Biotech Company Award". Gerald Dekker, chairman of the jury, presented the price to Tim Kievits, CEO of PamGene. The Andersen Biotechnology Group aims to support starting biotech companies in The Netherlands and Belgium through this initiative.
Important criteria for the jury were an innovative product or concept generating revenues within 2-3 years protected by a strong intellectual property position. The jury also looked into the business models and marketing strategies of the fifteen companies in the competition.
The jury consisted of:
- Gerald M. Dekker RA; responsible for the Biotechnology Group in The Netherlands;
- Ing. Paul A. SchrÖder, President of the NVP (Dutch Association for Venture Capital and Private Equity);
- Dr. Ir. Nettie R.M. Buitelaar, Managing Director Biopartner Network;
- Prof. Dr. Cornelis P. Hollenberg, Chairman Department of Microbiology Heinrich-Heine-Universität Düsseldorf.
The jury has chosen PamGene as the winner because of its proven patented technology that can be marketed in the short term. PamGene expects the introduction of commercial products in the second quarter of 2002. Also the partnerships with several European research institutes and Japanese Olympus played a significant role in the decision. Finally the international character of the investors and PamGene's knowledge of its competitors and developments in the market were mentioned as important factors for future success.
About PamGene
PamGene is a post-genomics biotech company, which has patented technologies for a second-generation microarray platform and an expression profiling system. The PamChip™ allows faster, more accurate and cost-effective test results. The technology will be commercialized in academic research, pharma and biotech R&D, health management and non-pharma life sciences such as agricultural applications and food. PamGene, financed by amongst others GIMV, Alta Partners and Life Sciences Partners has entered into strategic partnership with Olympus. The present workforce of 27 is expected to grow to approximately 60 employees in 2002. PamGene is currently working on its next financing round.
Contacts:
Tim Kievits, Chief Executive Officer, PamGene B.V.
Telephone: +31 73 615 8080
Email:
This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
www.pamgene.com
| |
